Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting
Tegavivint was generally well tolerated and demonstrated monotherapy clinical responses with clear on-target Wnt/b-catenin pathway inhibition in patients with Wnt-pathway mutated advanced hepatocellular carcinoma (HCC) In second- and third-line patients, tegavivint achieved an overall...
Tegavivint was generally well tolerated and demonstrated monotherapy clinical responses with clear on-target Wnt/b-catenin pathway inhibition in patients with Wnt-pathway mutated advanced hepatocellular carcinoma (HCC) In second- and third-line patients, tegavivint achieved an overall...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.